Neuroprotection of Anakinra on peripheral nerve neurodegeneration in single and combination protocols with TTR siRNA in a transgenic mouse model for human V30M transthyretin by unknown
POSTER PRESENTATION Open Access
Neuroprotection of Anakinra on peripheral nerve
neurodegeneration in single and combination
protocols with TTR siRNA in a transgenic mouse
model for human V30M transthyretin
Maria João Saraiva*, Paula Gonçalves, Diana Martins, Nádia Pereira Gonçalves
From First European Congress on Hereditary ATTR amyloidosis
Paris, France. 2-3 November 2015
Background
We previously showed the properties of interleukin-1b
antagonist Anakinra on unmyelinated nerve fibers pro-
tection in a transgenic mouse model for human V30M
transthyretin. In these studies, Anakinra decreased,
among other markers, nerve levels of IL-1b, NF-B and
activated-caspase 3, associated with a decrease in TTR-
non fibrillar deposition.
In the present work, we compared the efficacy of
other compounds under human therapeutical trials for
Familial Amyloidotic Polyneuropathy (FAP) in the same
animal model, having 5 months of age.
Methods
V30M transgenic mice were treated daily with subcuta-
neous injections of Anakinra at 25 mg/kg over 6 weeks.
Age-matched controls were injected with phosphate buf-
fer saline (PBS). TTR siRNA, at a concentration of
1 mg/kg was injected in the tail vein for 4 weeks. One
intravenous injection was performed per week and ani-
mals were euthanized 48 h after the last injection.
Untreated age-matched controls received vehicle intra-
venously. Anakinra plus TTR siRNA combination ther-
apy was performed using the same therapeutical design.
In addition, other V30M mice group was treated with
Tafamidis meglumine with 3 subcutaneous injections
weekly, over 6 weeks. Controls received meglumine
alone. Finally, combination strategy with Doxycycline/
TUDCA was also achieved in V30M mice. Animals
were treated with 8 mg/kg Doxycycline daily in the
drinking water and received intraperitoneal injections of
500 mg/kg TUDCA twice a week for 4 weeks. Controls
were injected with intraperitoneal PBS.
After mice sacrifice, nerves were collected into a
0.1 M sodium cacodylate solution containing 1.25% glu-
taraldehyde and 4% paraformaldehyde for posterior fiber
counting. Nerves from animals treated with Anakinra,
TTR siRNA or both agents combined were also ana-
lyzed by immunohistochemistry for inflammatory and
apoptotic markers, namely NF-B transcription factor,
IL-1b and FAS death receptor.
Results
In contrast with Anakinra treatment alone, no differ-
ences in both myelinated and unmyelinated fiber density
as compared with vehicle were found for the other
tested compounds. However, combined Anakinra and
siRNA administration resulted in increased density of
unmyelinated fibers as compared to controls. Efficiency
of Anakinra as a neuroprotective molecule was corrobo-
rated in sciatic nerve analyses of NF-B, FAS death
receptor and IL-1b in animals treated with a combina-
tion of Anakinra and siRNA, since these markers were
found downregulated in animals receiving this combined
therapy. Mice treatment with single protocols of siRNA,
Tafamidis or Doxycycline/TUDCA, did not change
levels of the selected biomarkers.
Conclusion
Anakinra should be considered for its potential in single
and/or combination protocols for FAP studies.
Instituto de Inovação e Investigação em Saúde (I3S), Instituto de Biologia
Molecular e Celular (IBMC), Universidade do Porto, Molecular Neurobiology
Unit, 4150-180, Porto, Portugal
Saraiva et al. Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):P13
http://www.ojrd.com/content/10/S1/P13
© 2015 Saraiva et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 2 November 2015
doi:10.1186/1750-1172-10-S1-P13
Cite this article as: Saraiva et al.: Neuroprotection of Anakinra on
peripheral nerve neurodegeneration in single and combination
protocols with TTR siRNA in a transgenic mouse model for human
V30M transthyretin. Orphanet Journal of Rare Diseases 2015 10(Suppl 1):
P13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Saraiva et al. Orphanet Journal of Rare Diseases 2015, 10(Suppl 1):P13
http://www.ojrd.com/content/10/S1/P13
Page 2 of 2
